Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.

Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE.

Science. 2012 Mar 23;335(6075):1503-6. doi: 10.1126/science.1217697. Epub 2012 Feb 9.

2.

Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels.

Lee CY, Tse W, Smith JD, Landreth GE.

J Biol Chem. 2012 Jan 13;287(3):2032-44. doi: 10.1074/jbc.M111.295451. Epub 2011 Nov 30.

3.

Astrocytes contain amyloid-β annular protofibrils in Alzheimer's disease brains.

Lasagna-Reeves CA, Kayed R.

FEBS Lett. 2011 Oct 3;585(19):3052-7. doi: 10.1016/j.febslet.2011.08.027. Epub 2011 Aug 24.

4.

Nuclear receptors as therapeutic targets for Alzheimer's disease.

Mandrekar-Colucci S, Landreth GE.

Expert Opin Ther Targets. 2011 Sep;15(9):1085-97. doi: 10.1517/14728222.2011.594043. Epub 2011 Jul 1. Review.

5.

Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis.

Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JÅ, Holtzman DM, Heneka MT.

J Neurosci. 2011 May 11;31(19):7049-59. doi: 10.1523/JNEUROSCI.6546-10.2011.

6.

Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways.

Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, Derudas B, Mayi T, Bories G, Tailleux A, Haulon S, Zawadzki C, Jude B, Staels B.

Circ Res. 2011 Apr 15;108(8):985-95. doi: 10.1161/CIRCRESAHA.110.233775. Epub 2011 Feb 24.

7.

Decreased clearance of CNS beta-amyloid in Alzheimer's disease.

Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ.

Science. 2010 Dec 24;330(6012):1774. doi: 10.1126/science.1197623. Epub 2010 Dec 9.

8.

ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.

Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, Chan J, Fan J, Collins J, Wellington CL.

J Biol Chem. 2010 Oct 29;285(44):34144-54. doi: 10.1074/jbc.M110.108100. Epub 2010 Aug 25.

9.

Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S.

Dement Geriatr Cogn Disord. 2010;30(2):131-46. doi: 10.1159/000318845. Epub 2010 Aug 21.

10.

Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status.

Rodriguez-Rivera J, Denner L, Dineley KT.

Behav Brain Res. 2011 Jan 1;216(1):255-61. doi: 10.1016/j.bbr.2010.08.002. Epub 2010 Aug 13.

11.

Neuroinflammatory processes in Alzheimer's disease.

Heneka MT, O'Banion MK, Terwel D, Kummer MP.

J Neural Transm (Vienna). 2010 Aug;117(8):919-47. doi: 10.1007/s00702-010-0438-z. Epub 2010 Jul 15. Review.

PMID:
20632195
12.

Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks.

Palop JJ, Mucke L.

Nat Neurosci. 2010 Jul;13(7):812-8. doi: 10.1038/nn.2583. Review.

13.

Control of macrophage activation and function by PPARs.

Chawla A.

Circ Res. 2010 May 28;106(10):1559-69. doi: 10.1161/CIRCRESAHA.110.216523. Review.

14.

Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.

Fitz NF, Cronican A, Pham T, Fogg A, Fauq AH, Chapman R, Lefterov I, Koldamova R.

J Neurosci. 2010 May 19;30(20):6862-72. doi: 10.1523/JNEUROSCI.1051-10.2010.

15.

Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells.

Glass CK, Saijo K.

Nat Rev Immunol. 2010 May;10(5):365-76. doi: 10.1038/nri2748. Review.

PMID:
20414208
16.

Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin.

Hemauer SJ, Patrikeeva SL, Nanovskaya TN, Hankins GD, Ahmed MS.

Am J Obstet Gynecol. 2010 Apr;202(4):383.e1-7. doi: 10.1016/j.ajog.2010.01.035.

17.

Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology.

Escribano L, Simón AM, Gimeno E, Cuadrado-Tejedor M, López de Maturana R, García-Osta A, Ricobaraza A, Pérez-Mediavilla A, Del Río J, Frechilla D.

Neuropsychopharmacology. 2010 Jun;35(7):1593-604. doi: 10.1038/npp.2010.32. Epub 2010 Mar 24.

18.

Microglia and inflammation in Alzheimer's disease.

Mandrekar-Colucci S, Landreth GE.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):156-67. Review.

19.

Alzheimer's disease.

Querfurth HW, LaFerla FM.

N Engl J Med. 2010 Jan 28;362(4):329-44. doi: 10.1056/NEJMra0909142. Review. No abstract available. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588.

PMID:
20107219
20.

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.

Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T.

Neurobiol Aging. 2011 Sep;32(9):1626-33. doi: 10.1016/j.neurobiolaging.2009.10.009. Epub 2009 Nov 17.

PMID:
19923038

Supplemental Content

Support Center